ASTRAZENECA PLC

NYSE:AZN

Pharmaceutical Preparations·CAMBRIDGE

AstraZeneca plc (AZ) is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

Prospectuses & Registrations

29 shown

Filed	Form	Description
2/27/26	424B2	424B2	→
2/26/26	FWP	FWP	→
2/25/26	424B2	424B2	→
2/2/26	S-8	S-8	→
1/21/25	F-6	F-6	→
3/19/24	F-3ASR	F-3ASR	→
↓

Ownership

38 shown

Filed	Form	Description
10/28/24	SC 13G	SC 13G	→
10/11/24	SC 13G	SC 13G	→
2/12/24	SC 13G/A	SC 13G/A	→
1/24/24	SC 13G/A	SC 13G/A	→
11/16/23	SC 13D/A	SC 13D/A	→
11/9/23	SC 13D	SC 13D	→
↓

Other Filings

40 shown

Filed	Form	Description
3/4/26	CERT	NYSE CERTIFICATION	→
3/3/26	8-A12B	FORM 8-A12B	→
2/6/26	SCHEDULE 13G/A	SCHEDULE 13G/A	→
2/6/26	SCHEDULE 13D/A	SCHEDULE 13D/A	→
1/30/26	25	FORM 25	→
1/22/26	CERT	NYSE CERTIFICATION	→
↓

Filing History(1003 filings)

TypeDateAccessionPeriodSize

6-K

Mar 6, 2026

0001654954-26-001966DIRECTOR/PDMR SHAREHOLDING

Mar 6, 2026

45.6 KB

6-K

Mar 6, 2026

0001654954-26-001963DIRECTOR/PDMR SHAREHOLDING

Mar 6, 2026

68.9 KB

6-K

Mar 6, 2026

0001654954-26-001961DIRECTOR/PDMR SHAREHOLDING

Mar 6, 2026

71.0 KB

CERT

Mar 4, 2026

0000876661-26-000201NYSE CERTIFICATION

—

172.9 KB

8-A12B

Mar 3, 2026

0001104659-26-022824FORM 8-A12B

—

22.7 KB

6-K

Mar 2, 2026

0001104659-26-022240FORM 6-K

Mar 2, 2026

894.8 KB

6-K

Mar 2, 2026

0001654954-26-001728TOTAL VOTING RIGHTS

Mar 2, 2026

19.2 KB

424B2

Feb 27, 2026

0001104659-26-021545424B2

—

1.0 MB

6-K

Feb 26, 2026

0001654954-26-001589ASTRAZENECA PRICES A $2BN BOND OFFERING

Feb 26, 2026

23.8 KB

FWP

Feb 26, 2026

0001104659-26-019812FWP

—

37.6 KB

6-K

Feb 25, 2026

0001654954-26-001536FILING OF FORM 20-F WITH SEC

Feb 25, 2026

18.0 KB

424B2

Feb 25, 2026

0001104659-26-019420424B2

—

828.6 KB

IRANNOTICE

Feb 24, 2026

0001104659-26-019141IRANNOTICE

—

6.4 KB

20-F

Feb 24, 2026

0001104659-26-01913020-F

Dec 31, 2025

121.9 MB

6-K

Feb 24, 2026

0001104659-26-019110FORM 6-K

Feb 24, 2026

22.9 MB

6-K

Feb 24, 2026

0001654954-26-001483ANNUAL FINANCIAL REPORT

Feb 24, 2026

21.0 KB

6-K

Feb 24, 2026

0001654954-26-001481DIRECTORATE CHANGE

Feb 24, 2026

21.5 KB

6-K

Feb 20, 2026

0001654954-26-001409FIXED-DURATION CALQUENCE COMBO APPROVED IN US

Feb 20, 2026

43.1 KB

6-K

Feb 10, 2026

0001654954-26-001073FINAL RESULTS

Feb 10, 2026

1.6 MB

SCHEDULE 13G/A

Feb 6, 2026

0001104659-26-011303

—

9.6 KB

SCHEDULE 13D/A

Feb 6, 2026

0001104659-26-011298

—

41.4 KB

6-K

Feb 3, 2026

0001654954-26-000857UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION

Feb 3, 2026

51.2 KB

S-8

Feb 2, 2026

0001104659-26-009284FORM S-8

—

1.3 MB

6-K

Feb 2, 2026

0001654954-26-000824TOTAL VOTING RIGHTS

Feb 2, 2026

19.4 KB

6-K

Feb 2, 2026

0001654954-26-000795IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER

Feb 2, 2026

59.8 KB

25 filings shown